Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Monday 22 September, 2008

Lipoxen PLC

SMi Drug Delivery Global Summ

RNS Number : 9431D
Lipoxen PLC
22 September 2008
 



Lipoxen Plc ('Lipoxen' or 'the Company')



Lipoxen to present at the SMi Drug Delivery Global Summit


Presentation to discuss Lipoxen's clinical stage products and technology platforms for the delivery of siRNA therapeutics and DNA vaccines



London, UK, 22 September 2008 - Lipoxen PLC, (AIM:LPX) a biopharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, today announces that Chief Operating Officer, Dr Peter Laing, will present at the SMi Drug Delivery Global Summit. The conference takes place September 22 - 23, 2008 at The Copthorne Tara Hotel, LondonUK.  


Dr Laing's presentation, entitled Delivery of protein and peptide drugs with polysialic acid: a new technology platform in the clinic, will give a brief corporate overview of Lipoxen and discuss topics such as Lipoxen's versatile enabling technology, PolyXenTM, which uses polysialic acid (PSA) to prolong the active life, and improve the pharmacokinetics, of therapeutic peptides and proteins. Dr Laing will also discuss Lipoxen's liposomal therapeutics platforms for the liposomal delivery of siRNA therapeutics and DNA vaccines using non-toxic vehicles suitable for chronic administration. 


Dr Laing's presentation will take place on Monday, September 22nd, at 11:40 a.m. For more information on the conference, of which Lipoxen is also a sponsor, please visit www.smi-online.co.uk/events/overview.asp?is=4&ref=2944.


- Ends -


 Enquiries 


Lipoxen PLC


M. Scott Maguire, Chief Executive Officer

+44 (0)20 7691 3583 



Landsbanki Securities (UK) Limited (nominated adviser)


Shaun Dobson / Claes Spång 

+44 (0)20 7426 9000



Citigate Dewe Rogerson

+44 (0)20 7638 9571

David Dible / Heather Keohane




Notes to Editors

Further information on Lipoxen 


Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important biologicals such as erythropoietin (EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a long-acting human insulin and ErepoXen[R], long-acting EPO. These novel products, which are based on Lipoxen's proprietary PolyXen[R] technology, each address markets in excess of US$1 billion. 


Lipoxen's technology is designed to improve the stability, biological half-life and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery technologies, ImuXen[R] and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary delivery technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited (one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license agreements in place with Baxter International and InterVet, a leading animal health company.


Lipoxen was admitted to trading on the AIM Market of the London Stock Exchange in January 2006.


This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims', 'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results, performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAVLLBLVKBBBBB